Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update

Dow Jones10-31

By Kosaku Narioka

Takeda Pharmaceutical reported a second-quarter net profit and raised its annual earnings forecasts.

The Japanese drugmaker said Thursday that it booked a net profit of 92.0 billion yen, equivalent to $599.6 million, for the three months ended Sept. 30, compared with a net loss of Y48.0 billion in the year-earlier period. That beat the estimate of Y50.0 billion from a poll of analysts by data provider Visible Alpha.

Second-quarter revenue rose 13% on year to Y1.176 trillion. Sales of ulcerative colitis drug Entyvio rose 20% to Y238.9 billion and sales of plasma-derived products also grew 20% to Y264.2 billion.

Sales of Vyvanse dropped 14% to Y88.5 billion. Takeda lost U.S. market exclusivity for the blockbuster drug for attention-deficit hyperactivity disorder in August last year.

Takeda raised its earnings guidance, saying the loss of market share to generic versions of Vyvanse has been milder than anticipated.

For the fiscal year ending March 2025, it projected net profit to fall 53% to Y68.00 billion, compared with its previous expectation of a 60% drop, and revenue to increase 5.1% to Y4.480 trillion, compared with the 2.0% rise forecast previously.

Write to Kosaku Narioka at kosaku.narioka@wsj.com

(END) Dow Jones Newswires

October 31, 2024 03:12 ET (07:12 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479724562?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 15:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479724562","market":"nz","top_or_hot":-1,"title":"Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kosaku Narioka \n</p>\n<pre>\n \n</pre>\n<p>\n  Takeda Pharmaceutical reported a second-quarter net profit and raised its annual earnings forecasts. \n</p>\n<p>\n  The Japanese drugmaker said Thursday that it booked a net profit of 92.0 billion yen, equivalent to $599.6 million, for the three months ended Sept. 30, compared with a net loss of Y48.0 billion in the year-earlier period. That beat the estimate of Y50.0 billion from a poll of analysts by data provider Visible Alpha. \n</p>\n<p>\n  Second-quarter revenue rose 13% on year to Y1.176 trillion. Sales of ulcerative colitis drug Entyvio rose 20% to Y238.9 billion and sales of plasma-derived products also grew 20% to Y264.2 billion. \n</p>\n<p>\n  Sales of Vyvanse dropped 14% to Y88.5 billion. Takeda lost U.S. market exclusivity for the blockbuster drug for attention-deficit hyperactivity disorder in August last year. \n</p>\n<p>\n  Takeda raised its earnings guidance, saying the loss of market share to generic versions of Vyvanse has been milder than anticipated. \n</p>\n<p>\n  For the fiscal year ending March 2025, it projected net profit to fall 53% to Y68.00 billion, compared with its previous expectation of a 60% drop, and revenue to increase 5.1% to Y4.480 trillion, compared with the 2.0% rise forecast previously. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2024 03:12 ET (07:12 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 15:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kosaku Narioka \n\n\n \n\n\n  Takeda Pharmaceutical reported a second-quarter net profit and raised its annual earnings forecasts. \n\n\n  The Japanese drugmaker said Thursday that it booked a net profit of...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479724562","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479724562","pubTimestamp":1730358720,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Takeda Pharmaceutical reported a second-quarter net profit and raised its annual earnings forecasts.The Japanese drugmaker said Thursday that it booked a net profit of 92.0 billion yen, equivalent to $599.6 million, for the three months ended Sept. 30, compared with a net loss of Y48.0 billion in the year-earlier period. That beat the estimate of Y50.0 billion from a poll of analysts by data provider Visible Alpha.Second-quarter revenue rose 13% on year to Y1.176 trillion. Sales of ulcerative colitis drug Entyvio rose 20% to Y238.9 billion and sales of plasma-derived products also grew 20% to Y264.2 billion.Sales of Vyvanse dropped 14% to Y88.5 billion. Takeda lost U.S. market exclusivity for the blockbuster drug for attention-deficit hyperactivity disorder in August last year.Takeda raised its earnings guidance, saying the loss of market share to generic versions of Vyvanse has been milder than anticipated.For the fiscal year ending March 2025, it projected net profit to fall 53% to Y","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药"},"translate_title":"武田制药公布季度净利润，上调指引——更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"By Kosaku Narioka \n\n\n \n\n\n  Takeda Pharmaceutical reported a second-quarter net profit and raised its annual earnings forecasts. \n\n\n  The Japanese drugmaker said Thursday that it booked a net profit of 92.0 billion yen, equivalent to $599.6 million, for the three months ended Sept. 30, compared with a net loss of Y48.0 billion in the year-earlier period. That beat the estimate of Y50.0 billion from a poll of analysts by data provider Visible Alpha. \n\n\n  Second-quarter revenue rose 13% on year to Y1.176 trillion. Sales of ulcerative colitis drug Entyvio rose 20% to Y238.9 billion and sales of plasma-derived products also grew 20% to Y264.2 billion. \n\n\n  Sales of Vyvanse dropped 14% to Y88.5 billion. Takeda lost U.S. market exclusivity for the blockbuster drug for attention-deficit hyperactivity disorder in August last year. \n\n\n  Takeda raised its earnings guidance, saying the loss of market share to generic versions of Vyvanse has been milder than anticipated. \n\n\n  For the fiscal year ending March 2025, it projected net profit to fall 53% to Y68.00 billion, compared with its previous expectation of a 60% drop, and revenue to increase 5.1% to Y4.480 trillion, compared with the 2.0% rise forecast previously. \n\n\n \n\n\n  Write to Kosaku Narioka at kosaku.narioka@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 03:12 ET (07:12 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479724562"}